文献速递血栓与止血

癌症患者偶发性肺栓塞的临床特征、管理与结局

Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients.
PubMed 文献 · Blood Adv · 2020-01-01

该研究为1:2配对病例对照研究,纳入2006至2016年MD Anderson癌症中心急诊就诊的904例偶发性肺栓塞(IPE)确诊患者。IPE多发生于癌症诊断后第一年,接受细胞毒性化疗者风险近三倍;住院死亡率1.9%,7天和30天死亡率分别为1.8%和9.9%,显著高于对照组,且与总生存期缩短相关。

要点

  • 癌症诊断后第一年及接受细胞毒性化疗者IPE风险显著升高。
  • IPE患者7天和30天死亡率显著高于对照组,且与总生存期缩短独立相关。
  • 约20.9%患者合并偶发性静脉血栓栓塞,亦与总生存期缩短相关。

核心结论

  • 癌症患者偶发性肺栓塞事件与不良结局相关,需制定类似症状性肺栓塞的规范管理方案。

研究设计与样本

  • 1:2配对病例对照研究,纳入2006年1月1日至2016年1月1日MD Anderson癌症中心急诊就诊的904例确诊IPE患者,按倾向性评分匹配对照。

主要发现

  • IPE常发生于癌症诊断后第一年(OR 2.79,95%CI 2.37-3.29,P<.001)。
  • 接受细胞毒性化疗者发生IPE风险近三倍(OR 2.87,95%CI 2.42-3.40,P<.001)。
  • 住院死亡率为1.9%;病例组7天和30天死亡率分别为1.8%和9.9%,显著高于对照组的0.2%和3.1%(P<.001)。
  • IPE与总生存期缩短相关(HR 1.93,95%CI 1.74-2.14,P<.001)。
  • 189例(20.9%)合并偶发性静脉血栓栓塞,亦与总生存期缩短相关(HR 1.65,95%CI 1.21-2.25,P=.001)。

临床怎么用

  • 对癌症患者应警惕IPE发生,尤其在其诊断后第一年及接受细胞毒性化疗期间。
  • IPE患者的管理计划应与症状性肺栓塞类似,以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incidental pulmonary embolisms (IPEs) are common in cancer patients. Examining the characteristics and outcomes of IPEs in cancer patients can help to ensure proper management, promoting better outcomes. To determine the clinical characteristics, management, and outcomes of IPEs for cancer patients, we conducted a 1:2 ratio case-control study and identified all consecutive patients with IPE who visited the emergency department at The University of Texas MD Anderson Cancer Center between 1 January 2006 and 1 January 2016. Each IPE case was matched with 2 controls using a propensity score obtained using logistic regression for IPE status with other factors affecting overall survival. A total of 904 confirmed cases were included in the analysis. IPE frequently occurred during the first year after cancer diagnosis (odds ratio [OR], 2.79; 95% confidence interval [95% CI], 2.37-3.29; P < .001). Patients receiving cytotoxic chemotherapy had a nearly threefold greater risk of developing IPE (OR, 2.87; 95% CI, 2.42-3.40; P < .001). In-hospital mortality was 1.9%. The 7- and 30-day mortality rates among the cases were 1.8% and 9.9%, respectively, which was significantly higher than in the control groups: 0.2% and 3.1%, respectively (P < .001). IPE was associated with reduced overall survival (hazard ratio [HR], 1.93; 95% CI, 1.74-2.14; P < .001). Concurrent incidental venous thromboembolism was identified in 189 of the patients (20.9%) and was also associated with reduced overall survival (HR, 1.65; 95% CI, 1.21-2.25; P = .001). Our results show that IPE events are associated with poor outcomes in cancer patients. Proper management plans similar to those of symptomatic pulmonary embolisms are essential.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Qdaisat A, Kamal M, Al-Breiki A, et al. Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients. Blood Adv. 2020. PMID: 32311012. doi:10.1182/bloodadvances.2020001501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。